Open Access
Numéro
Cah. Myol.
Numéro 23, juillet 2021
Page(s) 32 - 37
Section Prix sfm
DOI https://doi.org/10.1051/myolog/202123012
Publié en ligne 2 août 2021
  1. Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neuro! 2017; 264: 621–30. [CrossRef] [Google Scholar]
  2. On behalf of the Pompe Advance Study Consortium, Hahn SH, Kronn D, Leslie ND, Pena LDM, Tanpaiboon P, et al. Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: Advance, a phase IV, open-label, prospective study. Genet Med 2018; 20: 1284–94. [CrossRef] [Google Scholar]
  3. Solé G, Salort-Campana E, Pereon Y, Stojkovic T, Wahbi K, Cintas P, et al. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neuro! (Paris) 2020; 176: 507–15. [CrossRef] [Google Scholar]
  4. Van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ eta!.A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Eng! J Med 2010; 362: 1396–406. [CrossRef] [PubMed] [Google Scholar]
  5. De las Vecillas Sánchez L, Alenazy L, Garcia-Neuer M, Castells M Drug hypersensitivity and desensitizations: mechanisms and new approaches. Int J Mo! Sci 2017; 18: 1316. [CrossRef] [Google Scholar]
  6. DeVries JM, Kuperus E, Hoogeveen-Westerveld M, Kroos MA, Wens SCA, Stok M, et al. Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy. Genet Med 2017; 19, 90–7. [CrossRef] [Google Scholar]
  7. Gallay L, Petiot P, Durieu I, Streichenberger N, Berard F SWORD: a simplified desensitization protocol for enzyme replacement therapy in adult Pompe disease. Neuromusc Disord 2016; 26 : 801–4. [CrossRef] [Google Scholar]
  8. Muraro A, Roberts G, Worm M, Biló MB, Brockow K, Fernández Rivas M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014; 69: 1026–45. [CrossRef] [PubMed] [Google Scholar]
  9. Sanofi G. MYOZYME Summary of product characteristics [Internet]. 2009. Available from: https://www.ema.europa.eu/en/documents/product-information/myozyme-epar-product-information_en.pdf. [Google Scholar]
  10. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018; 73: 1393–414. [CrossRef] [PubMed] [Google Scholar]
  11. Demoly P, Chabane H, Fontaine JF, de Boissieu D, Ryan D, Angier E, et al. Development of algorithms for the diagnosis and management of acute allergy in primary practice. World Allergy OrgJ 2019; 12: 100022. [CrossRef] [Google Scholar]
  12. Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Exp Rev Clin Immunol 2012; 8: 43–54. [CrossRef] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.